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Abstract
Background: Individuals who reach exceptional longevity 
(100+ years of age) free of common chronic age diseases 
(i.e. ‘dodgers’) arguably represent the paradigm of suc-
cessful aging in humans. As such, identification of poten-
tial biomarkers associated with this phenomenon is of 
medical interest.
Methods: We measured serum levels of galectin-3 and 
osteopontin, both of which have been shown to be linked 
with major chronic or aging-related disorders in younger 
populations, in centenarian ‘dodgers’ (n = 81; 40 men; 
100–104 years) and healthy controls (n = 41; 24 men, 70–80 
years).
Results: Both biomarkers showed significantly lower 
values (p < 0.001) in the former (galectin-3: 2.4±1.7 vs. 
4.8±2.8 ng/mL; osteopontin: 38.1±27.7 vs. 72.6±33.1 μg/mL). 
Logistic regression analysis identified the combination 
of these two biomarkers as a significant predictor vari-
able associated with successful aging regardless of sex 
(p < 0.001). The area under the curve (AUC) classified the 
ability of galectin-3 and osteopontin to predict the likeli-
hood of successful aging as ‘fair’ (AUC = 0.75) and ‘good’ 
(AUC = 0.80), respectively. Particularly, the combination 
of the two biomarkers showed good discriminatory power 
for successful aging (AUC = 0.86), with sensitivity = 83% 
and specificity = 74%.
Conclusions: Lower levels of both galectin-3 and osteo-
pontin are associated with successful aging, representing 
potential biomarkers of this condition. Our cross-sectional 
data must be however approached with caution. Further 
research is necessary to replicate the present preliminary 
results in other cohorts and to identify the potential use of 
galectin-3 and osteopontin as potential targets (or at least 
predictors) in future personalized anti-aging therapies.
Keywords: age; anti-aging; biomarkers; health.
Introduction
Galectin-3, a β-galactoside-binding lectin, has been recently 
postulated as a potential biomarker for screening, diagno-
sis and prognosis of metabolic disorders, cardiac fibrosis 
and heart failure [1–6]. Circulating galectin-3 is also strongly 
associated with atrial fibrillation [7, 8], adverse cardiac 
events in patients with chronic stable angina [9], as well as 
mortality in hemodialysis patients [10]. Inhibition of galec-
tin-3 has in fact been proposed as a therapeutic target to 
prevent a wide range of diseases [11–13]. On the other hand, 
galectin-3 levels increase with age [14].
Osteopontin, a non-collagenous bone matrix glyco-
protein expressed in various cell types, also represents a 
potential, novel prognostic biomarker in several disease 
conditions such as obesity, diabetes, osteoporosis as well 
as myocardial fibrosis and heart failure associated with 
(or independent of) aging or following myocardial infarc-
tion [15–19]. In a rat model of aging, Miller et al. showed 
that an increased gene expression of osteopontin corre-
lated with the development of progressive aortic vascu-
lopathy [20]. Additionally, elevated levels of osteopontin 
are linked with aging decline in the capacity for muscle 
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regeneration [21], with myoblasts producing this molecule 
to modulate myogenic and inflammatory processes in the 
early stages of muscle regeneration [22].
Despite growing data supporting that galectin-3 and 
osteopontin can be used as biomarkers of several disease 
conditions, no data are yet available on healthy centenar-
ians, a population segment that is the paradigm of suc-
cessful aging in our increasingly older societies. Although 
centenarians (i.e. age  ≥ 100 years) represent the paradigm 
for exceptional longevity (20+ years more than the average 
life expectancy in the Western world), they are usually an 
heterogeneous group of subjects who can either delay 
(‘delayers’), survive (‘survivors’) or even escape common 
age-related diseases (‘dodgers’) [23]. The current study 
was performed to determine if the two aforementioned 
biomarkers are associated with successful aging. To this 
end, we measured serum galectin-3 and osteopontin con-
centrations in healthy centenarians, i.e. ‘dodgers’, and 
healthy younger elders (controls).
Materials and methods
Participants
The study protocol complied with the tenets of the Declaration of 
Helsinki and was approved by the Local Ethics Committee. All study 
participants provided their written informed consent. We studied 81 
healthy centenarians, i.e. ‘dodgers’, (40 men; mean±SD age: 101±1 
years; age range: 100−104 years) and 46 healthy younger elderly peo-
ple (24 men; 75±3 years; 70−80 years). The participants’ ages were 
defined by the dates of birth as stated on identity cards. All of them 
were Caucasian Whites ascertained to be of Italian descent (Northern 
Italy, mainly from Lombardy and Piedmont).
The centenarians ‘dodgers’ were ascertained mainly via general 
practitioners in the community; they represent a convenience sample 
that has been previously described in detail [24–26]. The history of 
past and current diseases was accurately collected, checking the cen-
tenarians’ medical documentation and the current drug therapy. All 
of them were free of major age-related diseases, i.e. severe cognitive 
impairment, clinically evident cancer, cardiovascular disease (CVD), 
renal insufficiency, or severe physical impairment. Only part of this 
group had decreased visual or auditory acuity.
The controls were sex-matched with centenarians and randomly 
selected from elderly subjects who participated in previous research 
[27]. They were in apparent good physical health, with exclusion 
criteria being: presence of CVD or cerebrovascular disease, cancer, 
dementia, chronic autoimmune or inflammatory disorders, renal or 
hepatic failure, and major psychiatric disorders.
Galectin-3 and osteopontin measurements
Serum galectin-3 (Biovendor, Modrice, Czech Republic) and oste-
opontin levels were determined using commercially available 
enzyme-linked immunosorbent assay kits according to the manu-
facturers’ protocols (Human Osteopontin Quantikine kit, R&D 
 Systems, Minneapolis, MN, USA). Details for each assay are avail-
able from the authors upon request. For all assays, the intra- and 
inter-assay coefficients of variation were  < 7% and  < 9%, respec-
tively. Each sample was analyzed in duplicate, and the mean value 
of the two measures was used for the analyses. Laboratory person-
nel were blinded with regard to subjects’ group (centenarians or 
controls).
Statistical analysis
Statistical analyses were performed with the IBM SPSS 22.0 package 
for MAC (SPSS, Inc., Chicago, IL, USA) and G*Power 3 program for 
MAC. Descriptive data are expressed as means±SD as well as medians 
and ranges. Since the data were not normally distributed, we used 
the non-parametric Mann-Whitney U-test to compare serum bio-
marker levels among the two groups.
The optimal cut-off point for the association of the two biomark-
ers with the likelihood of being a centenarian ‘dodger’ was deter-
mined by receiver operating characteristic (ROC) curves. The Youden 
index was used to define the optimal cut-off point, and areas under 
the curve (AUC) and 95% confidence interval were also calculated. 
AUC values of  ≥ 0.90 are “excellent”, and values between 0.80 and 
0.90, 0.70 and 0.79 and  < 0.70 are considered to be “good”, “fair”, and 
“poor”, respectively [28]. Logistic regression analysis with the for-
ward conditional selection method was used to find a combination of 
galectin-3 and osteopontin that would be potentially associated with 
successful aging. The predicted probability (PP) value was calculated 
for each logistic regression analysis. A leave-one-out cross validation 
was performed for assessing if the equations could be generalized to 
an independent data set.
Results
Differences in serum biomarkers between 
groups
The mean values of both biomarkers were significantly 
lower in centenarians ‘dodgers’ compared with controls 
(p < 0.001, Table 1; see also dot plot in Figure 1).
Multivariate analysis
Logistic regression analysis identified the combination 
of the two biomarkers as a significant predictor vari-
able associated with successful aging regardless of sex 
(p < 0.001). The equation defined by the analysis was: 
PP =  1/[1+1/exp(4.084–0.656 × (galectin-3)+0.962 × (osteo-
pontin)]. The leave-one-out cross validation analysis con-
firmed the coefficients.
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ROC curve analysis
The ROC curve results of galectin-3 and osteopontin (either 
alone or in combination) as independent variables asso-
ciated with successful aging are shown in Table  2 and 
Figure 2. The AUC of serum biomarkers classified the ability 
of galectin-3 and osteopontin serum levels to predict the 
likelihood of successful aging as ‘fair’ and ‘good’, respec-
tively. Particularly, the combination of the two biomarkers 
showed good discriminatory power for successful aging 
(AUC = 0.86), with sensitivity = 83% and specificity = 74%.
Discussion
This is the first attempt to assess the association of galec-
tin-3 and osteopontin with successful aging by studying the 
blood of centenarians ‘dodgers’. These unique individuals 
showed lower concentrations of both biomarkers compared 
with healthy younger elderly people and logistic regression 
analysis identified the combination of the two biomarkers as 
a significant predictor of successful aging regardless of sex, 
with good discriminatory power. We believe these findings 
are potentially interesting. Indeed, our societies are aging 
and identification of possible blood biomarkers of success-
ful aging could help identify ‘low’ or ‘high risk’ subjects and 
design individualized effective therapies and/or preven-
tive measures. On the other hand, cross-sectional data on 
serum levels of these or other biomarkers can be influenced 
by many confounders including genetics and interpretation 
of results must be approached with caution [29]. Further 
research is also needed with larger cohorts.
It has been previously shown that galectin-3 
levels correlate with risk factors of CVD such as blood 
Table 1: Serum levels of biomarkers (mean±SD; median and range) and age by group. 
 
 
Both sexes 
 
p-Value 
 
Statistical powera 
 
Optimal total sample size, nb
Centenarians, n = 81  Controls, n = 46
Galectin-3, ng/mL   2.4±1.7
2.1 (0.33, 7.95)
  4.8±2.8
4.5 (0.83, 9.3)
   < 0.001  99%  22
Osteopontin, μg/L  38.1±27.7
32.5 (2.5, 110.0)
  72.6±33.1
65.0 (17.5, 192.5)
   < 0.001  99%  28
Biomarkers data did not follow a normal distribution. aStatistical post-hoc power analysis to detect differences between group means with a 
significance level (α) of 0.05 (two-tailed). bEstimated optimal sample size (enrollment ratio 1:1) to obtain a statistical power  ≥ 90% to detect 
difference between group means with a significance level (α) of 0.05 (two-tailed).
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Figure 1: Values for galectin-3 (A) and osteopontin (B) by group (centenarians [“dodgers”] and controls).
Table 2: Receiver operating characteristic (ROC) results for galectin-3 and osteopontin as independent variables associated with success-
ful aging. 
Biomarker   Optimal cut-off  AUC  95% CI  p-Value  Standard error  Sensitivity, %  Specificity, %
Galectin-3    < 5.3 ng/mL  0.75  0.66–0.84   < 0.001  0.046  46  96
Osteopontin    < 42.2 μg/L  0.80  0.72–0.87   < 0.001  0.038  89  64
2-Biomarker panel   ≥ 0.6  0.86  0.79–0.92   < 0.001  0.033  83  74
CI, Confidence interval; AUC, area under the curve.
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pressure, serum lipids, body mass index, renal function 
and  N-terminal pro-B-type natriuretic peptide [14]. More-
over, galectin-3 circulating levels have been directly asso-
ciated with cardiac fibrosis, structural remodeling and 
the related myocardiocyte dysfunction, heart failure and 
arrhythmias (particularly atrial fibrillation) [1–8], all of 
them representing age-related co-morbidities which may 
lead to mortality in aged individuals. Inhibition of syn-
thesis/activity of galectin-3 represents a potential therapy 
against cardiac fibrosis and remodeling, and also against 
heart failure [12, 30–32]. More interestingly, it was previ-
ously reported that galectin-3 is strongly associated with 
age [14, 33]. Notably, a study with a cohort of 7968 adults 
(mean age of 50±13 years) which were followed longitu-
dinally (median follow-up of ~10 years) found that, after 
correction for ‘classical’ CVD risk factors (smoking, blood 
pressure, cholesterol and diabetes), galectin-3 levels inde-
pendently predicted all-cause mortality [14].
Osteopontin seems to be involved in the progression 
of both instability-induced and aging-associated sponta-
neous osteoarthritis [34]. Paliwal et al. also suggested that 
tissues of old people overexpress osteopontin, which is 
a physiological phenomenon as we age but on the other 
hand can potentially lead to pathologies [21]. Addition-
ally, osteopontin levels are increased in the cerebrospinal 
fluid of patients with Alzheimer’s disease and correlate 
with cognitive decline [35]. Most importantly, osteopontin 
has an important role in many disease conditions that are 
prevalent among older people such as obesity, diabetes, 
myocardial fibrosis, heart failure, inflammation, osteo-
porosis, and is also involved in the aging decline in the 
capacity for skeletal muscle regeneration [15–19, 21, 36]. 
Regarding a major cause of morbidity and mortality in 
aging humans, CVD, osteopontin plasma levels are not 
only elevated in heart failure patients with left ventricu-
lar dysfunction (median age between 50 and 60 years) 
but also correlate with disease severity and risk for subse-
quent death [15]. In summary, our data suggest that lower 
levels of both galectin-3 and osteopontin are associated 
with successful aging, representing potential biomark-
ers of this condition. Further research, including ideally 
longitudinal designs, is necessary to corroborate the data 
reported here in larger cohorts of a different geographic/
ethic origin and (ii) to determine whether these biomark-
ers might be considered as potential targets (or at least 
predictors) in future personalized anti-aging therapies.
Author contributions: All the authors have accepted respon-
sibility for the entire content of this submitted manuscript 
and approved submission.
Financial support: Research in the field of aging by 
A. Lucia is funded by Fondo de Investigaciones Sanitarias 
(FIS, grant #PI15/00558) and Fondos Feder.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played 
no role in the study design; in the collection, analysis, and 
interpretation of data; in the writing of the report; or in the 
decision to submit the report for publication.
References
1. McCullough PA. Practical experience using galectin-3 in heart 
failure. Clin Chem Lab Med 2014;52:1425–31.
2. Filipe MD, Meijers WC, Rogier van der Velde A, de Boer RA. 
 Galectin-3 and heart failure: prognosis, prediction and clinical 
utility. Clin Chim Acta 2015;443:48–56.
3. Lippi G, Cervellin G. Risk assessment of post-infarction heart 
failure. Systematic review on the role of emerging biomarkers. 
Crit Rev Clin Lab Sci 2014;51:13–29.
4. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, 
et al. Galectin-3, a marker of cardiac fibrosis, predicts 
incident heart failure in the community. J Am Coll Cardiol 
2012;60:1249–56.
5. Pugliese G, Iacobini C, Pesce CM, Menini S. Galectin-3: an emerg-
ing all-out player in metabolic disorders and their complications. 
Glycobiology 2014;25:136–50.
6. Pugliese G, Iacobini C, Ricci C, Blasetti Fantauzzi C, 
 Menini S. Galectin-3 in diabetic patients. Clin Chem Lab Med 
2014;52:1413–23.
7. Lippi G, Cervellin G, Sanchis-Gomar F. Galectin-3 in atrial 
fibrillation: simple bystander, player or both? Clin Biochem 
2015;48:818–22.
8. Gurses KM, Yalcin MU, Kocyigit D, Canpinar H, Evranos B, 
Yorgun H, et al. Effects of persistent atrial fibrillation on serum 
galectin-3 levels. Am J Cardiol 2015;115:647–51.
1.0 Source of the curve
Galectin-3
Osteopontin
PP-value (defined by the
two above mentioned
biomarkers)
0.8
0.6
0.4Se
ns
itiv
ity
0.2
0
0 0.2 0.4
1-Specificity
0.6 0.8 1.0
Figure 2: Results of receiver operating characteristic (ROC) curves 
for the combination of biomarkers associated with successful aging 
(galectin-3 and osteopontin) vs. individual serum markers.
Brought to you by | New York University Bobst Library Technical Services
Authenticated
Download Date | 1/22/16 11:45 AM
Sanchis-Gomar et al.: Biomarkers in centenarians      5
9. Minoretti P, Falcone C, Calcagnino M, Emanuele E, Buzzi MP, 
Coen E, et al. Prognostic significance of plasma osteopon-
tin levels in patients with chronic stable angina. Eur Heart J 
2006;27:802–7.
10. Ozkan G, Ulusoy S, Mentese A, Guvercin B, Karahan SC, Yavuz A, 
et al. Can be galectin-3 a novel marker in determining mortality 
in hemodialysis patients? Clin Biochem 2015;48:768–73.
11. Schelbert EB, Fonarow GC, Bonow RO, Butler J, Gheorghiade M. 
Therapeutic targets in heart failure: refocusing on the myocar-
dial interstitium. J Am Coll Cardiol 2014;63:2188–98.
12. Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, 
et al. Genetic and pharmacological inhibition of galectin-3 
prevents cardiac remodeling by interfering with myocardial 
fibrogenesis. Circ Heart Fail 2013;6:107–17.
13. Jalife J. Mechanisms of persistent atrial fibrillation. Curr Opin 
Cardiol 2014;29:20–7.
14. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, 
van Gilst WH, Hillege HL, et al. The fibrosis marker galectin-3 and 
outcome in the general population. J Intern Med 2012;272:55–64.
15. Rosenberg M, Zugck C, Nelles M, Juenger C, Frank D, 
 Remppis A, et al. Osteopontin, a new prognostic biomarker 
in patients with chronic heart failure. Circ Heart Fail  
2008;1:43–9.
16. Singh M, Foster CR, Dalal S, Singh K. Role of  osteopontin 
in heart failure associated with aging. Heart Fail Rev 
2010;15:487–94.
17. Lopez B, Gonzalez A, Lindner D, Westermann D, Ravassa S, 
Beaumont J, et al. Osteopontin-mediated myocardial fibro-
sis in heart failure: a role for lysyl oxidase? Cardiovasc Res 
2013;99:111–20.
18. Kahles F, Findeisen HM, Bruemmer D. Osteopontin: a novel 
regulator at the cross roads of inflammation, obesity and diabe-
tes. Mol Metab 2014;3:384–93.
19. Kavukcuoglu NB, Denhardt DT, Guzelsu N, Mann AB. Osteopon-
tin deficiency and aging on nanomechanics of mouse bone. J 
Biomed Mater Res A 2007;83:136–44.
20. Miller SJ, Watson WC, Kerr KA, Labarrere CA, Chen NX, Deeg MA, 
et al. Development of progressive aortic vasculopathy 
in a rat model of aging. Am J Physiol Heart Circ Physiol 
2007;293:H2634–43.
21. Paliwal P, Pishesha N, Wijaya D, Conboy IM. Age dependent 
increase in the levels of osteopontin inhibits skeletal muscle 
regeneration. Aging (Albany NY) 2012;4:553–66.
22. Uaesoontrachoon K, Yoo HJ, Tudor EM, Pike RN, Mackie EJ, 
Pagel CN. Osteopontin and skeletal muscle myoblasts: asso-
ciation with muscle regeneration and regulation of myoblast 
function in vitro. Int J Biochem Cell Biol 2008;40:2303–14.
23. Andersen SL, Sebastiani P, Dworkis DA, Feldman L, Perls TT. 
Health span approximates life span among many supercente-
narians: compression of morbidity at the approximate limit of 
life span. J Gerontol A Biol Sci Med Sci 2012;67:395–405.
24. Emanuele E, Minoretti P, Pareja-Galeano H, Sanchis-Gomar F, 
Garatachea N, Lucia A. Serum irisin levels, precocious myocar-
dial infarction, and healthy exceptional longevity. Am J Med 
2014;127:888–90.
25. Emanuele E, Minoretti P, Sanchis-Gomar F, Pareja-Galeano H, 
Yilmaz Y, Garatachea N, et al. Can enhanced autophagy be asso-
ciated with human longevity? Serum levels of the autophagy 
biomarker beclin-1 are increased in healthy centenarians. 
Rejuvenation Res 2014;17:518–24.
26. Sanchis-Gomar F, Pareja-Galeano H, Santos-Lozano A, 
 Garatachea N, Fiuza-Luces C, Venturini L, et al. A preliminary 
candidate approach identifies the combination of chemerin, 
fetuin-A, and fibroblast growth factors 19 and 21 as a potential 
biomarker panel of successful aging. Age (Dordr) 2015;37:9776.
27. Emanuele E, Fontana JM, Minoretti P, Geroldi D. Preliminary 
evidence of a genetic association between chromosome 9p21.3 
and human longevity. Rejuvenation Res 2010;13:23–6.
28. Trost SG, Fees BS, Haar SJ, Murray AD, Crowe LK. Identification 
and validity of accelerometer cut-points for toddlers. Obesity 
(Silver Spring) 2012;20:2317–9.
29. Hausman DB, Fischer JG, Johnson MA. Protein, lipid, and hema-
tological biomarkers in centenarians: definitions, interpretation 
and relationships with health. Maturitas 2012;71:205–12.
30. Liu YH, D’Ambrosio M, Liao TD, Peng H, Rhaleb NE, Sharma U, 
et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac 
remodeling and dysfunction induced by galectin-3, a mamma-
lian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ 
Physiol 2009;296:H404–12.
31. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, 
de Boer RA, et al. Galectin-3 mediates aldosterone-induced 
vascular fibrosis. Arterioscler Thromb Vasc Biol 2013;33:67–75.
32. Lax A, Sanchez-Mas J, Asensio-Lopez MC, Fernandez-Del 
 Palacio MJ, Caballero L, Garrido IP, et al. Mineralocorticoid 
receptor antagonists modulate galectin-3 and interleukin-33/
ST2 signaling in left ventricular systolic dysfunction after acute 
myocardial infarction. JACC Heart Fail 2015;3:50–8.
33. Lippi G, Salvagno GL, Bonfanti L, Cervellin G. Relationship 
between serum galectin-3 values and demographical or bio-
chemical variables in patients without acute coronary syn-
drome. Int J Cardiol 2014;171:270–1.
34. Matsui Y, Iwasaki N, Kon S, Takahashi D, Morimoto J, Denhardt DT, 
et al. Accelerated development of aging-associated and 
instability-induced osteoarthritis in osteopontin-deficient mice. 
Arthritis Rheum 2009;60:2362–71.
35. Comi C, Carecchio M, Chiocchetti A, Nicola S, Galimberti D, 
Fenoglio C, et al. Osteopontin is increased in the cerebro-
spinal fluid of patients with Alzheimer’s disease and its 
levels correlate with cognitive decline. J Alzheimers Dis 
2010;19:1143–8.
36. Frangogiannis NG. Matricellular proteins in cardiac adaptation 
and disease. Physiol Rev 2012;92:635–88.
Brought to you by | New York University Bobst Library Technical Services
Authenticated
Download Date | 1/22/16 11:45 AM
